These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31078244)

  • 1. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know?
    Dwadasi S; Israel A; Rubin DT
    Gastrointest Endosc Clin N Am; 2019 Jul; 29(3):405-419. PubMed ID: 31078244
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
    Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
    Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
    [No Abstract]   [Full Text] [Related]  

  • 3. New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis.
    Eliadou E; Day AS; Thompson-Fawcett MW; Gearry RB; Rowbotham DS; Walmsley R; Schultz M; Inns SJ; ;
    N Z Med J; 2015 Oct; 128(1423):63-76. PubMed ID: 26645757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
    Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ulcerative Colitis.
    Sonnenberg E; Siegmund B
    Digestion; 2016; 94(4):181-185. PubMed ID: 27931025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
    Reinisch W; Louis E; Danese S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Perspectives in inflammatory bowel diseases treatment].
    Jalocha L; Wojtuń S; Dyrla P; Błaszak A; Wojtkowiak M; Zyśko B; Stelmaszuk T; Gil J
    Pol Merkur Lekarski; 2009 May; 26(155):556-8. PubMed ID: 19606725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced therapies in inflammatory bowel disease: Special considerations.
    Williams AJ
    J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():22-24. PubMed ID: 33817851
    [No Abstract]   [Full Text] [Related]  

  • 11. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
    Menter A; Strober BE; Kaplan DH; Kivelevitch D; Prater EF; Stoff B; Armstrong AW; Connor C; Cordoro KM; Davis DMR; Elewski BE; Gelfand JM; Gordon KB; Gottlieb AB; Kavanaugh A; Kiselica M; Korman NJ; Kroshinsky D; Lebwohl M; Leonardi CL; Lichten J; Lim HW; Mehta NN; Paller AS; Parra SL; Pathy AL; Rupani RN; Siegel M; Wong EB; Wu JJ; Hariharan V; Elmets CA
    J Am Acad Dermatol; 2019 Apr; 80(4):1029-1072. PubMed ID: 30772098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab.
    Gregory MH; Ciorba MA; Deepak P; Christophi GP
    Inflamm Bowel Dis; 2019 Jun; 25(7):e87-e88. PubMed ID: 30753456
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of tofacitinib treatment in ulcerative colitis.
    Panés J; Gisbert JP
    Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease.
    Tighe D; McNamara D
    World J Gastroenterol; 2017 Jan; 23(3):414-425. PubMed ID: 28210077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease.
    Cheon JH
    J Gastroenterol Hepatol; 2017 Apr; 32(4):769-777. PubMed ID: 27723166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB
    Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-TNF-α agents and serum lipids in inflammatory bowel diseases.
    Kalkan Ç; Karakaya F; Törüner M; Çetinkaya H; Soykan I
    Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):e46-7. PubMed ID: 26852393
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.
    Gonczi L; Gecse KB; Vegh Z; Kurti Z; Rutka M; Farkas K; Golovics PA; Lovasz BD; Banai J; Bene L; Gasztonyi B; Kristof T; Lakatos L; Miheller P; Nagy F; Palatka K; Papp M; Patai A; Salamon A; Szamosi T; Szepes Z; Toth GT; Vincze A; Szalay B; Molnar T; Lakatos PL
    Inflamm Bowel Dis; 2017 Nov; 23(11):1908-1915. PubMed ID: 28922253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States.
    Milev S; DiBonaventura MD; Quon P; Wern Goh J; Bourret J; Peeples-Lamirande K; Soonasra A; Cappelleri JC; Quirk D
    J Med Econ; 2019 Sep; 22(9):859-868. PubMed ID: 31012362
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.